Characteristics and response to certain cancer chemotherapeutic agents of an acute lymphocytic leukemia arising in a BALB-c times DBA-2F1 mouse.
D000477:Alkylating Agents / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004048:Diethylamines / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005029:Ethylenediamines / Q000627:therapeutic use; D005449:Fluorenes / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D007369:Interferon Inducers / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D011239:Prednisolone / Q000627:therapeutic use; D013892:Thioxanthenes / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004048:Diethylamines; D005029:Ethylenediamines; D005449:Fluorenes; D007369:Interferon Inducers; D013892:Thioxanthenes; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D005472:Fluorouracil; D008727:Methotrexate